IMD 101
Alternative Names: IMD-101Latest Information Update: 06 Mar 2024
At a glance
- Originator Shanghai Affinity Biopharmaceutical
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Bladder cancer; Solid tumours
Most Recent Events
- 06 Mar 2024 Phase-I clinical trials in Bladder cancer (Late-stage disease, Second-line therapy or greater) in Australia (IV) (Prior to March 2024) (ACTRN12623001217695p)
- 06 Mar 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia (IV) (prior to March 2024) (ACTRN12623001217695p)
- 22 Dec 2023 IMD 101 is available for licensing as of 22 Dec 2023. http://www.affinitybiopharma.com/en/cooperation.html (Shanghai Affinity Biopharmaceutical website, December 2023)